Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0

作者：

Brown, Jennifer R. ^{[1
]}

Eichhorst, Barbara ^{[2
]}

Ghia, Paolo ^{[3
,4
]}

Kater, A. P. ^{[5
]}

Li, Jianyong ^{[6
]}

Khurana, Sudha ^{[7
]}

Elhamy, Mostafa ^{[7
]}

Wang, Min Hui ^{[7
]}

Seymour, John F. ^{[8
,9
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp Cologne, Cologne, Germany

[3] Univ Vita Salute Raffaele, Milan, Italy

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Amsterdam UMC, Amsterdam, Netherlands

[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China

[7] Acerta Pharma, San Francisco, CA USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Royal Melbourne Hosp, Melbourne, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-092

引用

页码：S221 / S222

页数：2

共 50 条

[41] Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).
Byrd, John C.
Jones, Jeffrey Alan
Furman, Richard R.
Stephens, Deborah Marie
Devereux, Steve
Brown, Jennifer R.
Hillmen, Peter
Hamdy, Ahmed M.
Fardis, Maria
Tawashi, Manal
Wang, Min Hui
Patel, Priti
Mittag, Diana
Krantz, Fanny
Rothbaum, Wayne
Izumi, Raquel
O'Brien, Susan Mary
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
Cramer, Paula
Fuerstenau, Moritz
Robrecht, Sandra
Giza, Adam
Fink, Anna
Fischer, Kirsten
Langerbeins, Petra
Al-Sawaf, Othman
Tausch, Eugen
Schneider, Christof
Schetelig, Johannes
Dreger, Peter
Boettcher, Sebastian
Kreuzer, Karl-Anton
Schilhabel, Anke
Brueggemann, Monika
Kneba, Michael
Wendtner, Clemens
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
[43] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Woyach, Jennifer
Ruppert, Amy S.
Perez, Gabriela
Booth, Allison M.
Feldman, Diane
Dib, Elie G.
Jatoi, Aminah
Le-Rademacher, Jennifer
Heerema, Nyla A.
Lozanski, Gerard
Little, Richard
Ding, Wei
Hill, Brian T.
Stone, Richard M.
Mandrekar, Sumithra J.
Byrd, John C.
BLOOD, 2019, 134
[44] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
Owen, Carolyn J.
Stewart, Douglas A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
[45] SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Stathis, Anastasios
Mey, Ulrich
Schar, Sami
Hitz, Felicitas
Pott, Christiane
Mach, Nicolas
Krasniqi, Fatime
Novak, Urban
Schmidt, Christian
Hohloch, Karin
Kienle, Dirk Lars
Hess, Dagmar
Moccia, Alden A.
Unterhalt, Michael
Eckhardt, Katrin
Hayoz, Stefanie
Forestieri, Gabriela
Rossi, Davide
Dirnhofer, Stefan
Ceriani, Luca
Sartori, Giulio
Bertoni, Francesco
Buske, Christian
Zucca, Emanuele
Hiddemann, Wolfgang
BLOOD ADVANCES, 2022, 6 (13) : 3911 - 3920
[46] An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
Chen, Christine I.
Paul, Harminder
Snitzler, Susi
Le, Lisa W.
Wei, Ellen Nong
Lau, Anthea
Johnston, James B.
Gibson, Spencer B.
Queau, Michelle L.
Trudel, Suzanne
BLOOD, 2015, 126 (23)
[47] Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Seymour, John F.
Byrd, John C.
Munir, Talha
Ghia, Paolo
Kater, Arnon P.
Chanan-Khan, Asher
Furman, Richard R.
O'Brien, Susan
Brown, Jennifer R.
Mato, Anthony R.
Stilgenbauer, Stephan
Fehn, Thomas
de Miranda, Paulo Andre P.
Higgins, Kara
John, Ellie
de Borja, Marianne
Jurczak, Wojciech
Woyach, Jennifer A.
BLOOD, 2022, 140 : 7050 - 7052
[48] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Cho, Sang Kyu
Manzoor, Beenish S.
Sail, Kavita R.
Parise, Helene
Ravelo, Arliene
Shapouri, Sheila
Kapustyan, Tatyana
Sharmokh, Simon
Virabhak, Suchin
Davids, Matthew S.
Johnson, Scott
PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
[49] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Sang Kyu Cho
Beenish S. Manzoor
Kavita R. Sail
Hélène Parisé
Arliene Ravelo
Sheila Shapouri
Tatyana Kapustyan
Simon Sharmokh
Suchin Virabhak
Matthew S. Davids
Scott Johnson
PharmacoEconomics, 2020, 38 : 941 - 951
[50] Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
Wierda, William G.
Kipps, Thomas J.
Duerig, Jan
Griskevicius, Laimonas
Stilgenbauer, Stephan
Mayer, Jiri
Smolej, Lukas
Hess, Georg
Griniute, Rasa
Hernandez-Ilizaliturri, Francisco J.
Padmanabhan, Swaminathan
Gorczyca, Michele
Chang, Chai-Ni
Chan, Geoffrey
Gupta, Ira
Nielsen, Tina G.
Russell, Charlotte A.
BLOOD, 2011, 117 (24) : 6450 - 6458

← 1 2 3 4 5 →